Sotera Health (NASDAQ:SHC) Stake Boosted by Rhumbline Advisers

Rhumbline Advisers boosted its holdings in Sotera Health (NASDAQ:SHC) by 3.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 399,171 shares of the company’s stock after purchasing an additional 14,616 shares during the quarter. Rhumbline Advisers owned approximately 0.14% of Sotera Health worth $5,461,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its stake in Sotera Health by 19.4% during the 3rd quarter. Geode Capital Management LLC now owns 2,755,391 shares of the company’s stock valued at $46,026,000 after purchasing an additional 447,186 shares during the period. Maven Securities LTD acquired a new position in shares of Sotera Health during the third quarter worth approximately $1,670,000. Cerity Partners LLC acquired a new position in shares of Sotera Health during the third quarter worth approximately $1,489,000. Neo Ivy Capital Management bought a new position in Sotera Health in the 3rd quarter worth approximately $720,000. Finally, Barclays PLC increased its position in Sotera Health by 169.8% in the 3rd quarter. Barclays PLC now owns 473,597 shares of the company’s stock valued at $7,909,000 after acquiring an additional 298,085 shares during the period. Institutional investors own 91.03% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on SHC. Barclays cut their target price on Sotera Health from $18.00 to $17.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. Royal Bank of Canada restated an “outperform” rating and issued a $17.00 price objective on shares of Sotera Health in a report on Thursday, November 21st. The Goldman Sachs Group started coverage on Sotera Health in a report on Friday, December 6th. They set a “neutral” rating and a $14.00 target price on the stock. Finally, Citigroup boosted their price target on shares of Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $16.08.

Sotera Health Stock Down 10.0 %

SHC opened at $12.28 on Friday. The company has a market capitalization of $3.48 billion, a P/E ratio of 49.12 and a beta of 1.91. The company has a debt-to-equity ratio of 4.91, a current ratio of 2.88 and a quick ratio of 2.61. The firm’s fifty day moving average price is $13.46 and its two-hundred day moving average price is $14.52. Sotera Health has a fifty-two week low of $10.71 and a fifty-two week high of $17.08.

Sotera Health Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.